Core Viewpoint - The illegal resale of medical insurance drugs has formed a black industrial chain, posing health risks to patients and severely undermining the security of the national medical insurance fund [1][2][3]. Group 1: Traditional Practices and Current Trends - Traditional practices involved drug dealers directly purchasing reimbursed drugs from patients at slightly higher than the purchase price but significantly lower than market price, exploiting patients' lack of understanding of medical insurance policies [1]. - Recent trends show that drug dealers have developed a complete chain from inducing patients to acquire drugs, to multi-level transactions, ultimately leading to market entry, often using online platforms and social media to gain patients' trust [2]. Group 2: Emerging Risks and Regulatory Challenges - The rise of internet healthcare and online drug purchasing may lead to new illegal drug resale methods, such as using fake accounts and orders to obtain medical insurance reimbursements [3]. - The expansion of medical insurance cross-regional settlements increases the risk of illegal drug resales across regions, necessitating enhanced regulatory measures [3]. Group 3: Regulatory Recommendations - To combat the growing issue of cross-regional drug resales, it is recommended that various departments establish information-sharing and joint law enforcement mechanisms to break down information barriers [3]. - Utilizing big data and artificial intelligence for real-time monitoring and analysis of medical insurance reimbursement and drug circulation data is essential to detect anomalies and improve regulatory precision [3].

Core Viewpoint - The article highlights a case of illegal drug sales in Yangzhou, emphasizing the importance of drug safety and the need for strict regulatory compliance in the pharmaceutical industry [1][2]. Group 1: Case Details - The Yangzhou Guangling District Market Supervision Administration exposed a case involving a clinic that sold two boxes of Fufang Danshen Diwan and several boxes of Shexiang Baoxinwan without proper procurement documentation [1]. - The clinic was fined 2,000 yuan and had its illegal gains confiscated due to its initial offense and cooperation with the investigation [1]. Group 2: Regulatory Implications - The case serves as a warning to drug-use units to strictly implement procurement systems and standardize supply channels, reflecting the market supervision department's zero-tolerance policy towards "reflow drugs" [2]. - "Reflow drugs" refer to medications that are purchased through insurance and then illegally resold, posing significant safety risks due to improper storage and potential adulteration [2]. Group 3: Consumer Guidance - The market supervision department advises consumers to check the traceability codes on drug packaging, which serve as an "electronic ID" to ensure the legitimacy of the product [2]. - Consumers are cautioned against purchasing drugs from unknown sources or those with damaged packaging, and not to sell expired medications to drug dealers [2].

Core Viewpoint - The article highlights the serious threat posed by "reflow drugs," which are pharmaceuticals that re-enter the market through unofficial channels, jeopardizing consumer safety and undermining the integrity of the healthcare system [1][2]. Group 1: Impact on Consumer Safety and Market Integrity - Reflow drugs pose significant risks to public health, as they may be expired or stored improperly, leading to ineffective treatment or worsening of conditions [2]. - The presence of reflow drugs disrupts the legitimate pharmaceutical market, harming the interests of legitimate companies and eroding healthcare funds [2]. - The unique traceability codes on drug packages serve as a safeguard against counterfeit and reflow drugs, with multiple scans indicating potential fraud [2]. Group 2: Law Enforcement and Regulatory Actions - The National Healthcare Security Administration has initiated a special action to combat the sale of reflow drugs, uncovering over 30,000 suspicious traceability code leads across various institutions [2][7]. - Notable cases include a pharmacy in Hunan that sold drugs with traceability codes linked to multiple regions, raising concerns about the legitimacy of their inventory [2]. - The article details organized crime involving reflow drugs, with significant financial implications, including cases where criminal groups operated across regions with transactions exceeding 100 million yuan [3]. Group 3: Mechanisms of Reflow Drug Distribution - The article outlines the methods by which reflow drugs are sold, including individuals purchasing drugs through insurance and reselling them, as well as collusion between drug dealers and pharmacies [4]. - A specific case illustrates how an individual exploited insurance accounts to sell drugs at below-market prices, leading to legal consequences [4][11]. - The article also describes how some pharmaceutical companies engage in fraudulent practices, such as falsifying invoices to disguise reflow drugs as legitimate products [5][12]. Group 4: Regulatory Framework and Future Measures - The establishment of a comprehensive drug traceability system is underway, with all medical institutions required to upload traceability data by January 2026 [7]. - The article notes that as of August, over 661.51 billion traceability codes have been collected, indicating a tightening regulatory framework against reflow drugs [7]. - Experts suggest that a unified data standard and deeper integration of regulatory platforms are necessary to effectively combat the issue of reflow drugs [8]. Group 5: Public Awareness and Legal Consequences - The article emphasizes the importance of public engagement in monitoring drug sales through traceability codes to ensure safety and protect healthcare funds [9]. - Legal experts advocate for stricter definitions and penalties for those involved in the reflow drug trade, including potential inclusion on blacklists for offenders [9]. - The article concludes that the current regulatory environment presents low costs for offenders and high costs for enforcement, necessitating legal reforms to deter such activities [9].

Core Insights - The provincial medical insurance flying inspections are being initiated across various regions, focusing on the issue of "return drugs" and fraudulent practices in medical insurance [1][2][3] Group 1: Inspection Overview - The provincial flying inspections will cover all medical service behaviors and costs from January 1, 2023, to December 31, 2024, with the possibility of extending checks to previous years or 2025 [1] - The inspections are organized in a collaborative manner involving provincial and municipal levels, with teams typically consisting of around 50 members, including experts from various fields [2] Group 2: Focus Areas - Key areas of inspection include medical institutions, retail pharmacies, insured individuals, and medical insurance handling agencies, with specific attention on self-inspection results in nine medical fields [3] - The "return drug" issue is highlighted, with a focus on tracking drug traceability codes to combat illegal resale practices [3][4] Group 3: Regulatory Actions - The inspections will lead to immediate reporting to drug regulatory authorities for any discovered illegal activities, including the sale of return drugs and counterfeit medications [4] - The National Medical Insurance Administration has previously recovered over 8 billion yuan through similar inspections, demonstrating the effectiveness of these regulatory measures [2]